United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP cut its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 22.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,463,891 shares of the biotechnology company's stock after selling 706,958 shares during the quarter. Wellington Management Group LLP owned 5.49% of United Therapeutics worth $869,359,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Wealthfront Advisers LLC increased its holdings in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. grew its position in shares of United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after buying an additional 32,213 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock worth $391,459,000 after buying an additional 45,566 shares during the last quarter. Pacer Advisors Inc. raised its holdings in United Therapeutics by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company's stock valued at $210,869,000 after acquiring an additional 30,931 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in United Therapeutics by 12.3% during the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company's stock valued at $164,978,000 after acquiring an additional 50,409 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Remove Ads

United Therapeutics Price Performance

NASDAQ:UTHR traded down $4.90 during midday trading on Thursday, reaching $307.36. 431,930 shares of the company traded hands, compared to its average volume of 450,164. The firm has a market capitalization of $13.80 billion, a price-to-earnings ratio of 13.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The company has a fifty day moving average price of $336.64 and a 200 day moving average price of $355.09. United Therapeutics Co. has a twelve month low of $227.75 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the previous year, the company posted $4.36 earnings per share. On average, equities research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UTHR. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.

Insider Buying and Selling at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $956,195.85. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,500 shares of company stock valued at $26,134,500 in the last ninety days. Company insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.